All Episodes
|
78
|
John Marchica

Podcast 78: Our Take, October 28, 2019

Oct 28, 2019

Episode Summary

In this week’s Our Take, we’re covering the latest events in Biogen, involving their second life for aducanumab.

Episode Notes

In this week’s Our Take, we’re covering the latest events in Biogen, involving their second life for aducanumab. To sign up for the weekly email brief, click here.

Other briefs include:

  • California releases its first report on drug pricing, in an effort to improve transparency.
  • Bristol-Myers Squibb-Pfizer Alliance is collaborating with Fitbit for atrial fibrillation detection.
  • Amazon is partnering with City of Hope to provide cancer support services to U.S. Amazon employees and their families.
  • Hackensack Meridian Health and Englewood Health have signed a definitive merger agreement.
  • RWJBarnabas Health has signed a non-binding letter of intent to acquire Trinitas Regional Medical Center and its affiliates.
  • Drug distributors McKesson, AmerisourceBergen, and Cardinal Health are discussing an agreement with state and local authorities to settle thousands of opioid-related lawsuits for $18 billion.

About Darwin Research Group

Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs
Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare
Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health
Podcast 194: Why Health Care Reform Keeps Failing w/ Dr. David Shulkin
Podcast 193: The New Model for Specialty Pharmacy w/ Jigar Thakkar, PharmD
Podcast 192: Making Value-Based Care Work at Scale w/ David Carmouche, MD
Podcast 191: Curing Nursing Burnout Through Education w/ Dr. Adele Webb
Podcast 190: The New Rules of Health System Leadership w/ John D’Angelo, MD, FACEP

Recommended Content

Browse Library
INsights
January 14, 2026

Darwin's Our Take: Lilly’s ‘triple G’ candidate exceeds analysts’ expectations

Read More
INsights
January 5, 2026

Darwin's Our Take: FDA approves Novo Nordisk’s Wegovy pill

Read More
INsights
December 22, 2025

Darwin's Our Take: Another 9 drugmakers agree to most-favored-nation pricing on certain products

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.